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Summary 
Endoplasmic Reticulum protein-29 (ERp29) is a chaperone protein that functions in 
the unfolding and escort of secretory proteins. Like other reticuloplasmins, ERp29 is 
believed to be involved in carcinogenesis. In breast cancer, expression of ERp29 is 
downregulated and there exists a negative association between level of ERp29 and 
breast cancer stage/grade. To elucidate the role of ERp29 in breast cancer progression, 
aggressive breast cancer cells - MDA-MB231 and BT549 - were stably transfected 
with ERp29-expressing vectors. Upon isolation of single stable clones, morphological 
change from a spindle-like fibroblastic to a typical cobble-stone-like epithelial 
phenotype was observed in both ERp29-overexpressing MDA-MB231 and BT549 
clones. This phenomenon is reminiscence of mesenchymal to epithelial transition 
(MET). 
In malignancy, epithelial to mesenchymal transition (EMT) is believed to facilitate 
metastasis by medicating cells’ escape from primary tumors. Its reverse, MET, has 
been considered both as counteract of EMT, thus preventing metastasis, as well as a 
mechanism employed by escaped cells to establish metastatic tumors at secondary 
sites, thus supporting metastasis. EMT/MET is characterized by morphological, 
molecular or behavioral changes in cells. In addition to the morphological change 
mentioned above, overexpression of ERp29 in MDA-MB231 cells induced behavioral 
changes typified by decrease in expression of mesenchymal cell markers (vimentin 
and fibronectin) and increase in expression of epithelial cell markers (E-cadherin, 
  v 
β-catenin, and cytokeratin-19). These changes were believed to be brought upon 
downregulation of E-cadherin repressors (SNAI1, SNAI2, ZEB2, and Twist). 
Furthermore, ERp29-overexpressing MDA-MB231 clones exhibited lower migration 
and invasion capacity, indication of behavioral MET. In contrast, overexpression of 
ERp29 in BT549 cells only reduced the expression of fibronectin without changes in 
other markers and transcriptional repressors, as well as in cells’ behavior.  
Further investigation into the morphologic MET revealed that the morphological 
alterations observed in both cell lines were characterized by rearrangement of actin 
cytoskeleton, from stress fiber to cortical actin formation. In addition, mechanistic 
studies demonstrated that the levels of tight junction protein, ZO-1, and apical-basal 
polarity proteins, Par3 and Scribble, were markedly increased by ERp29 and mainly 
localized at the membrane to enhance cell-cell contact and polarization. However, 
other polarity proteins, including CDC42, Par6 and aPKC, did not seem to be 
involved in the ERp29-induced epithelial morphogenesis.   
These findings demonstrated a novel function and mechanism of ERp29 in regulating 
epithelial plasticity. Though the consequences varied between cell lines (complete 
MET in MDA-MB231 cells and incomplete MET in BT549 cells), several common 
features were observed upon ERp29 overexpression; including rearrangement of actin 
cytoskeleton, regulation of cell-cell junctions, as well as cell polarization. Taken 
together, overexpression of ERp29 could reprogram aggressive breast cancer cells to 
induce MET and thus regulate metastasis.        
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Chapter 1: Introduction 
1.1 Breast cancer 
1.1.1 Incidence of breast cancer  
Each year cancer is claiming millions of lives and affecting millions more. In 
developed country it is the leading cause of death and is the second in developing 
countries (reviewed in Jemal et al. 2011). GLOBOCAN 2008 worldwide statistics 
estimated 12.7 million cancer cases and 7.6 million cancer deaths in 2008 alone. 
Economically, in United States of America alone, The National Institute of Health 
estimated overall costs of cancer in 2010 at $263.8 billion which include medical, 
morbidity, and indirect mortality costs. This burden of cancer continues to increase as 
a result of growing and aging population as well as adoption of cancer-associated 
lifestyle.  
Globally breast cancer is the most frequently diagnosed cancer in females (Jemal et al. 
2011) (Table 1-1). It is predicted to account for 23% (1.38 million) of the total new 
cancer cases in 2008. Improvement in early detection is answerable for this increase 
of breast cancer incidence rate which has continually risen in the past 25 years. The 
same reason, together with better treatments, helps in the decline of breast-cancer 
related deaths. Despite all this, breast cancer is still the leading cause of cancer death 
in women (Jemal et al. 2011) with estimated 14% (458,400) of total cancer deaths in 
2008, 90% of which is caused by metastatic breast cancer.  
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In Singapore, breast cancer is also one of the biggest cancer burdens. GLOBOCAN 
2002 worldwide statistics ranked Singapore as having the highest incidence and 
mortality of breast cancer in Asia. In addition, Singapore Cancer Registry reported 
that breast cancer is the top cancer type affecting females, as well as one with the 
most deaths. This phenomenon will likely still occur in the future as since 1960s, the 
incidence rate has progress upwardly.  
   
Type Ranking No.of cases %  of all cancers
Breast 1 1384155 22.9
Cervix Uteri 2 530232 8.8
Colorectum 3 571204 9.4
Lungs 4 515999 8.5
Stomach 5 348571 5.8
Corpus Uteri 6 288387 4.8
Liver 7 226312 3.7
Ovary 8 224747 3.7
Thyroid 9 163968 2.7
Leukaemia 10 154978 2.6
Estimated cancer cases affecting females worldwide
 
Table 1-1 Predicted top ten most frequent cancers affecting women worldwide in 2008. 
Adapted from J. Ferlay, F. Bray, P. Pisani and D.M. Parkin. GLOBOCAN 2008. Cancer 
Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 10. Lyon, France. 
International Agency for Research on Cancer. Year. Available at: http://globocan.iarc.fr/. Last 
accessed 05/04/2011. 
1.1.2 Classifications of breast cancer 
Vast portion of human cancers (~90%) are carcinomas, i.e. cancers that arise in cells 
derived from epithelial origins (Elenbaas et al. 2001). Likewise, majority of breast 
cancers also originate from epithelia. Based on the starting site, breast carcinomas can 
be classified into two groups, lobular carcinoma that starts form the milk-generating 
glands (lobules) and ductal carcinoma which generates from ducts/tubes that carry 
milk from lobules to the nipples. In rare cases, breast cancer can also arise from other 
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areas and other cell types of the breast. Based on the invasiveness, these groups can 
be further classified into noninvasive (in situ) or invasive (infiltrating) carcinoma. The 
later covers cancers that invade their surrounding tissues as well as those that have 
metastasized to secondary sites. The most common form of invasive breast cancer is 
ductal invasive carcinoma which accounts for 75% of total cases, followed by lobular 
invasive carcinoma (10-15% of total cases) (reviewed in Vincent-Salomon et al., 
2003). Other rare types such as metaplastic carcinoma, mucinous carcinoma, as well 
as cribriform carcinoma, have also been described. Each of these invasive breast 
cancer types accounts for less than 5% of total cases. Common sites for breast cancer 
to spread are bone, lung, and liver (Hasebe et al., 2008) and recently breast cancer 
metastasis to the stomach has been reported (Eo, 2008).  
Invasive carcinoma is of great interest because, as mentioned earlier, it is believed to 
be responsible for 90% of cancer deaths (Fidler, 2002). Furthermore at the time of 
diagnosis, at least half of patients present clinically detectable metastasis (DeVita, et 
al., 1975). In breast cancer, the 98% 5-year survival rate in noninvasive cancer drops 
if the cancer has spread (American Cancer Society. Cancer Facts & Figures 2010. 
Atlanta: American Cancer Society; 2010). The estimated survival rate falls to 84% if 
it only invades nearby tissues and 23% if it has metastasized to distant lymph nodes 
and organs.  
The development of metastasis, including that of breast carcinomas, comprises of 
series of events. First cells must acquire migration and invasion capacity to escape 
from the primary tumor, penetrate the local stroma, and intravasate into the 
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bloodstream. At secondary sites cells must then extravasate where they can remain 
solitary (micrometastasis) or expand to form metastatic carcinoma. It is believed that 
the developmental program EMT is reactivated to facilitate the escape of cancer cells 
from primary sites and MET to facilitate metastasis formation at secondary sites.  
 
1.2 EMT and MET 
Since more than a century ago, the existence of the two main cell types, epithelium 
and mesenchyme, has been recognized. Epithelial cells are polarized in such a way 
that the top and bottom can be visually defined as apical and basal domain 
respectively (apical-basal polarization). The filamentous actin is also polarized with 
circumferential arrangement. Neighbouring epithelial cells are connected laterally to 
each other through cell-cell junctions which include adherens junctions, tight 
junctions, gap junctions, and desmosomes. Due to these intercellular links, individual 
cell movement is inhibited. Instead, epithelial cells must migrate as a group. On the 
other hand, mesenchymal cells do not establish stable cell-cell contacts which allows 
for increased individual migratory capacity. The actin filaments consist of network of 
interacting fibers. In addition, compared to epithelia, mesenchymes have more 
elongated shape and front-to-back leading edge polarity (reviewed in De Wever et al., 
2008). Although fairly rigid, epithelial cells are known to possess the ability to form 
mesenchymal cells, a process termed epithelial to mesenchymal transition (EMT) 
(Figure 1-1). Likewise, mesenhcymes also have the capacity to transform to epithelia, 
namely epithelial-mesenchymal reverse transition (EMrT) or mesenchymal to 
epithelial transition (MET) (Lillie, 1908).  
EMT is a multistep process characterized by the loss of cell-cell junctions and 
reorganization of the cytoskeleton, which together result in the loss of apical-basal 
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cell polarity and the acquisition of spindle-shaped morphology (Huber et al., 2005). 
This is associated with decrease in epithelial markers and increase in mesenchymal 
markers as well as gain of invasion and migration capacity. Accordingly, there are 3 
aspects associated with EMT/MET; morphological, molecular, and behavioral 
alterations. Each of these elements will be explored further in subsequent sections.   
 
Figure 1-1 Illustration of EMT and its reversion MET. In the process of EMT, epithelial 
cells dissolve their cell-cell junctions, lose apical-basal polarity, and acquire mesenchymal 
properties characterized by stress fiber formation as well as increased migration and invasion 
capacity. During MET, mesencymal cells gain characteristics of epithelial cells.  
 
EMT is found to be indispensible for normal development of multicellular organisms. 
During embryonic development, EMT is crucial for the formation of three-layered 
embryo through gastrulation (reviewed in Thiery et al., 2009). It is also essential for 
various organ formations such as heart, musculoskeletal system, craniofacial structure, 
and peripheral nervous system. In adult, this process can be reactivated during wound 
healing as well as in pathological conditions such as organ fibrosis and carcinogenesis. 
The involvement of EMT in cancer progression was first suggested almost a decade 
ago (Thiery, 2002). Since then, it has been observed in variety of cancers such as 
ovarian, colon, oesophageal, as well as breast cancer (reviewed in Micalizzi et al., 
2010). Although sometimes debated (Tarin et al., 2005), EMT is widely accepted as 
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one of the key mechanisms that facilitates metastasis by enabling epithelial-derived 
cancer cells to adopt a migratory and invasive phenotype and promoting escape from 
the primary sites (Thiery, 2002). 
Of equal importance, MET is also heavily involved in embryonic development, where 
it alternates with EMT during the formation of heart and somite (reviewed in Chaffer 
et al., 2007). In addition, MET is also known to be vital for kidney ontogenesis. In 
carcinogenesis, while EMT is believed to transform epithelial cells to more motile 
appearance, MET has been explored to explain the histopathological similarities 
between primary and metastatic tumors. It is hypothesized that MET occurs at 
secondary sites where sticky epithelial cells are able to extravasate from the 
bloodstream and form secondary metastasis (Thiery, 2002). This theory, however, 
remains highly controversial. Several studies have disregarded the idea that MET is 
an integral part of metastasis (Tsuji et al., 2009; Graff et al., 2000; Friedl et al., 2003). 
Compared to EMT, MET is a relatively unknown subject as most studies have been 
devoted to unravel the mechanisms behind EMT. Therefore, in an effort to explain 
and illustrate in greater details, some of the discussions will be presented in the 
perspective of EMT.  
1.2.1 Morphological changes in EMT/MET 
Morphological change is the most obvious aspect and first indication of EMT/MET. 
During EMT the cuboidal epithelial cells are transformed into elongated spindle-like 
mesenchymal cells. This loss of epithelial morphology is contributed by the disruption 
of cell-cell junctions and apical-basal polarization as well as reorganization of actin 
cytoskeleton. Cell-cell junctions that are heavily studied in regards to EMT/MET are 
adherens and tight junctions. Despite their great importance in the formation and 
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maintenance of epithelial integrity, adherens junctions have been shown to be 
independent from morphological changes observed during EMT (Maeda et al., 2005; 
Bhowmick et al., 2001) and therefore will not be discussed in this section. 
Tight junctions comprise of transmembrane proteins (occludin and claudins) whose 
cytoplasmic domains interact with several zona occludens (ZO) to form plaques that 
associate with the cytoskeleton (Tsukita et al., 1997). These junctions serve as 
diffusion barrier for solutes and define the boundary between apical and basolateral 
membrane domains (Cereijido et al., 1998). Dissociation of tight junctions is 
considered to be the first step of EMT and formation of tight junctions the completion 
of MET (Lee et al., 2006). The formation of tight junctions is intimately linked to the 
proper polarization of cells which involves the participation of three polarity 
complexes; Par (Par3/Par6/aPKC) and Crumbs (Crumbs/PALS/PATJ) apical 
complexes which localized to the tight junctions and the Scribble (Scribble/Dlg/Lgl) 
basal complex (Dow et al., 2007). These polarity modules often antagonize each other 
to mediate their proper positioning and functions (Bilder et al., 2003). The loss of 
epithelial apical-basal polarization in EMT is attributed to the disruption of these 
proteins. Polarity modules, Par complex in particular, are also known to be essential 
for the assembly and maintenance of tight junctions (Izumi et al., 1998; Joberty et al., 
2000). The associations between polarity proteins and cancer progression are 
complicated; they can act as tumor suppressors through their polarization activity or 
as oncoproteins when recruited as positive mediator for oncogenic pathways. Par3, for 
example, is diminished during carcinogenesis leading to loss of polarity in EMT 
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(Wang et al., 2008) and Scribble is considered as tumor suppressors in various type of 
cancer (Dow et al., 2007). In contrast, Par6 is genetically amplified in breast tumors 
(Nolan et al., 2008) and activation or mislocalization of aPKC is considered as a 
factor that promotes tumor growth (Grifoni et al., 2007).  
        
Figure 1-2 Diagram of polarity and junctional complexes. Par and Crumbs complexes are 
targeted to the tight junctions, in the apical region. Scribble complex is located in the basal 
region of epithelial cells. These complexes positively and negatively regulate each other for 
their proper localizations and functions. 
The process of EMT also involves rearrangement of actin cytoskeleton from cortical 
actin to stress fiber formation. In MET, reorganization of the cytoskeleton is critical 
for the establishment of tight and adherens junctions as well as regulation of 
apical-basal polarity. One of the most well known regulators of cytoskeletal actin is 
the small GTPases family, in particular RhoA (Bishop et al., 2000). Role of RhoA in 
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EMT/MET depends on its effectors. Activation of RhoA is known to induce EMT 
where through its downstream target Rho-associated coiled-coil containing protein 
kinase (ROCK), it regulates actin stress fiber formation and fibroblastoid morphology 
(Bhowmick et al., 2001). On the other hand, the degradation of RhoA which results in 
the dissolution of tight junctions also leads to EMT (Ozdamar et al., 2005). mDia, 
another effector of RhoA is believed to be responsible for this effect (Ozdamar et al., 
2005).  
1.2.2 Molecular changes in EMT/MET 
Molecular changes in EMT/MET include regulation of epithelial markers (E-cadherin, 
cytoplasmic β-catenin, cytokeratins) and mesenchymal markers (fibronectin, vimentin, 
nuclear β-catenin, N-cadherin). Among the markers, E-cadherin is considered the 
master regulator of EMT/MET where loss of its function and/or expression is heavily 
involved in EMT (Thiery, 2002). Indeed, during development loss of E-cadherin has 
been observed at EMT sites (Damjanov et al., 1986; Tepass et al., 1996); accordingly 
it is expressed at sites of MET during kidney ontogenesis (Kuure et al., 2000). 
Furthermore, downregulation of E-cadherin expression is one of the most frequently 
reported characteristics of metastatic cancers (Birchmeier et al., 1994), and restoration 
of E-cadherin in cancer cells leads to suppression of invasive and metastatic ability of 
cancer (Vleminckx et al., 1991; Frixen et al., 1991; Perl et al., 1998). Loss of 
E-cadherin is particularly observed in invasive front of primary tumors; conversely its 
reexpression in metastatic tumors suggests that E-cadherin is involved in MET at 
secondary sites (Kowalski et al., 2003; Yates et al., 2007). In general, level of 
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E-cadherin in primary tumors is conversely related to cancer grade or patient survival 
(Birchmeier et al., 1994; Hirohashi, 1998).  
E-cadherin is a major component of adherens junctions in epithelial cells. It is a 
transmembrane glycoprotein whose extracellular domain mediates lateral cell-cell 
contacts by forming homotypic binding with E-cadherin of neighboring cells. Its 
cytoplasmic domain interacts with actin cytoskeleton via α-catenin and β-catenin. The 
loss of E-cadherin or its relocalization from cell membrane releases β-catenin which 
will translocate to nucleus where it functions in the Wnt pathway. In nucleus, 
β-catenin interacts with members of the T-cell factor/lymphoid enhancer factor 
(TCF/LEF) family of transcription factors and modulates expression of a large 
number of genes involved in cell proliferation, migration, invasion, and 
morphogenesis which further mediates the progress of EMT (Clevers, 2006). Loss of 
E-cadherin is also associated with the induction of N-cadherin, a phenomenon called 
cadherin switch (Christofori, 2003). While cadherin switch is important for the 
molecular as well as behavioral alteration of EMT, it has been shown to have little or 
no effect on the morphological aspect. In fact, switching from E-cadherin to 
N-cadherin protein expression occurs only after EMT-like morphological changes 
become apparent (Lindley et al., 2010). 
The loss of E-cadherin expression and/or function can be achieved by transcriptional 
repression, promoter hypermethylation, or gene mutation. The first mechanism has 
emerged as one of the critical steps driving EMT. Several transcription factors are 
known to regulate E-cadherin transcriptionally and they have been shown to regulate 
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EMT both in normal physiological and pathological conditions. The identified Snail 
(SNAI1 and SNAI2), ZEB (ZEB1 and ZEB2/SIP1), and the basic helix-loop-helix 
(TCF3/E2A, Twist, Id2, Id3) families bind to consensus E-boxes on the E-cadherin 
promoter thus repressing its expression (Huber et al., 2005; Peinado et al., 2007). In 
addition, these transcription factors are also known to regulate each other as well as 
the expression of other EMT-related genes, including tight junction components, 
desmosomes, and matrix metalloproteinases, as well as polarity proteins (reviewed in 
Xu et al., 2009; Moreno-Bueno et al., 2008). They are also responsible for the change 
of intermediate filaments from epithelial-cytokeratins to mesenchymal-vimentin. Thus 
the transcription factors are responsible for the programming of cells toward 
mesenchymal state. 
These transcription factors are closely associated with EMT/MET in both 
physiological and pathological conditions. In embryonic development, SNAI1 and 
SNAI2 are known to control gastrulation and neural-crest EMT in different species 
(Thiery, 2003). In cancer progression, SNAIl is associated with a diffuse tumor type 
in gastric carcinoma and ZEB2 is associated with intestinal-type gastric carcinoma 
(Hajra et al., 2002; Blanco et al., 2002; Rosivatz et al., 2002). Knockdown of Twist in 
cancer cells prevented metastasis and its overexpression results in repression of 
E-cadherin as well as complete EMT (Yang et al., 2004). Generally in the process of 
EMT, the changes in the transcriptional program described in this section are 
complemented by non-transcriptional changes (described earlier) that help define the 
changes in cytoskeletal organization and cell shape.  
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1.2.3 Behavioral changes in EMT/MET 
Migration is a fundamental ability of mesenchymes by which they can reach their 
destination to carry out their particular functions. Due to the intricate cell-cell 
junctions, this characteristic is absent in epithelial cells. Therefore, on top of the 
morphology and molecular alterations, epithelial cells undergoing EMT may also gain 
migratory as well as invasion capacity. During EMT, increased level of extracellular 
components including collagens and fibronectin is observed. These proteins stimulate 
integrin signaling and induce the formation of focal adhesion which facilitate 
migration (Imamichi et al., 2007; Zhao et al., 2009). The formation of focal adhesion 
is also induced by focal adhesion kinase that is activated upon downregulation of 
E-cadherin (Frame et al., 2008). Upregulation of N-cadherin, which is associated with 
loss of E-cadherin, also promotes cell migration as cell-cell contacts formed by 
N-cadherin are much weaker than those of E-cadherin (Cavallaro et al., 2002; Hsu et 
al., 1996).  
Increased migration capacity is often translated into invasive behavior as cancer cells 
express and activate their extracellular proteases, such as matrix metalloproteases 
(MMPs),  allowing them to degrade extracellular matrix proteins and escape their 
surrounding (Moustakas et al., 2007). The accumulation of nuclear β-catenin 
contributes to this phenomenon since together with TCF/LEF transcription factor, it 
regulates the expression of MMPs. In addition, Snail and ZEB transcription factor 
families are also known to induce the expression of these proteases (reviewed in Xu et 
al., 2009). 
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Studies have shown that EMT-cells which have gained motility are responsible for the 
degradation of surrounding matrix to enable invasion and are often found in the 
invasive front of primary tumors (Tsuji et al., 2009). On the other hand, induction of 
MET has been reported to suppress tumor growth and metastasis in vivo (Chiu et al., 
2009). It is worth noting that despite the indisputable involvement of EMT, it is not 
the only mechanism by which cells gain migration and invasion capacity in 
carcinogenesis. There exist other scenarios where cancer cells become more migratory 
and invasive without the occurrence of EMT (Pinkas et al., 2002; Wicki et al., 2006).  
1.2.4 EMT/MET in breast cancer and its clinical implications  
Like in other cancer types, the occurrence and therefore significance of EMT/MET in 
breast cancer progression had been debated. The main reason is intricacy in following 
EMT/MET in time and space, especially in the heterogeneous environment of breast 
carcinoma. Furthermore, due to its transient nature (where EMT is followed by MET) 
pathologists are finding it difficult to observe cells undergoing EMT in clinical 
samples. However, indirect evidences of the involvement of EMT in breast cancer 
progression have accumulated over the years.  
The existence of isolated single cells in ductal invasive carcinoma suggests the 
occurrence of EMT from this epithelial-origin cancer; as well as the intermixed of 
epithelial and non-epithelial cells in metaplastic carcinoma (reviewed in 
Vincent-Salomon et al., 2003). Furthermore, the phenotype of breast cancer 
micrometastases in lymph nodes and in the bone marrow also indicates that EMT 
occurs within the primary tumors (Braun et al., 1999). Loss of expression and/or 
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functions of epithelial marker, E-cadherin, is frequently observed in breast carcinoma 
(Berx et al., 1998; Cheng et al., 2001). On the other hand, the emergence of 
mesenchymal marker, vimentin, in epithelial cells of breast tumors correlates with a 
shorter post-operative survival of patients. The various repressors of E-cadherin also 
associates with breast cancer progression; their overexpression is positively related to 
tumor aggressiveness and recurrence, poor prognosis as well as survival (reviewed in 
Peinado et al., 2007). Microarray-based study revealed that the expression of EMT 
markers preferentially occurs in basal-like breast tumors which are related to their 
poor prognosis and distant metastasis (Sarrió et al., 2008). 
Direct evidence of EMT in breast cancer has recently been presented (Trimboli et al., 
2008). In the study, epithelial cells were tracked and found to give rise to stromal 
fibroblasts upon in vivo tumor induction by oncogene myc. These cells lacked 
epithelial-cytokeratins and E-cadherin while expressing mesenchymal-vimentin and 
fibronectin.  
Considering its involvement in cancer progression, in particular metastasis formation, 
targeting EMT may have significant therapeutic effects in preventing invasion as well 
as metastasis. Several marketed drugs such as PDGFR inhibitor imatinib (Gleevec), 
HER2 inhibitor trastuzumab (Herceptin), and EGFR inhibitor gefitinib (Iressa) have 
been shown to inhibit EMT in breast cancer progressions as well as cancer patients 
(reviewed in Huber et al., 2005). In contrast, treatments such as chronic chemotherapy 
with oxaliplatin and ionizing radiations have been shown to induce EMT (Yang et al., 
2006; Jung et al., 2007). Another reason for the urgency of EMT inhibition rises from 
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the fact that EMT confers drug resistance. Lung cancer cells that have undergone 
EMT are insensitive to the growth inhibitory effects of EGFR kinase inhibition 
(erotinib) as well as other EGFR inhibitors such as gefitinib and cetuximab (Thomson 
et al., 2005; Frederick et al., 2007; Fuchs et al., 2007). In addition, targeting EMT 
may also prevent recurrence as it has been associated with residual breast cancer cells 
that survive following conventional chemotherapy (Creighton et al., 2009). Therefore, 
understanding EMT/MET in breast cancer is of great importance as it may not only 
halt cancer progression to a metastatic state but also its recurrence.  
 
1.3 ERp29 
1.3.1 Structure and distribution 
ERp29 is a reticuloplasmin, protein that resides in the endoplasmic reticulum (ER) 
lumen. Hubbard’s group was the first to clone this protein from rat enamel cells 
(Demmer et al., 1997). Further studies unified various ERp29-homologues, 
unidentified liver spot 35 (UL35) and ERp31, as products of a single gene and 
correlated human ERp29 with cognate cDNA previously name ERp28 and ERp31 
(Hubbard et al., 2000a). The same group also isolated human ERp29 from liver and 
revealed striking homologies both in sequence and physical properties of the protein 
from both sources (Hubbard et al., 2000a). In fact, ERp29 is highly conserved among 
mammals, with homolog Windbeutel found in organism as primitive as Drosophila 
(Hubbard et al., 2000b). ERp29 is ubiquitously expressed in most if not all of fetal 
and adult mammalian cells and tissues with high level of expression examined in 
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secretory tissues such as adrenal, mammary, enamel, prostate, thyroid, and liver 
(Mkrtchian et al., 1998b; Hubbard et al., 2000a; Liepinsh et al., 2001; Sargsyan et al., 
2002b). These observations, together with the characteristics of its promoter (GC rich, 
absence of TATA box, and presence on multiple transcription start-sites) indicate that 
ERp29 is a constitutively expressed housekeeping gene with a function of general 
importance (Sargsyan et al., 2002a). 
ERp29 gene is mapped to chromosome 12q24.13 and contains three small exons 
separated by one small and one large introns (Sargsyan et al., 2002a). The predicted 
GC and E box elements within the promoter have been shown to interact with 
Sp1/Sp3 and USF1/USF2 transcription factors respectively. ERp29 gene encodes for 
261-residue protein that is of 25.6kDa in size (Demmer et al., 1997). Secondary 
structure analysis indicates that ERp29 is generally hydrophilic with a strong 
hydrophobic N-terminus containing ER-targeting peptide which will be cleaved in 
mature protein (Mkrtchian et al., 1998b). The C-terminus contains KEEL motif, a 
variant of ER-retention motif that is recognized by specific receptor that continually 
retrieves the protein from later compartment of secretory pathways and returns them 
to the ER (Mkrtchian et al., 1998b). 
Tertiary structure of ERp29 is characterized by two domains connected by a flexible 
linker (residue 149-159). The N-terminal domain has a typical α/β thioredoxin fold 
that is similar to that of protein disulfide isomerase (PDI) but without the 
double-cysteine motif important for disulfide-bond formation (Barak et al., 2009). 
The C-terminal domain shows high similarities to Windbeutel (Lippert et al., 2007; 
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Barak et al., 2009) and contains a novel helical fold (Liepinsh et al., 2001). In fact, 
the C-terminal domain of ERp29 can be exchanged with that of Windbeutel to process 
Pipe, a Windbeutel substrate (Nilson et al., 1998). Several conserved residues in helix 
8 (Glu222, Arg225, Lys228, and Leu 229) and helix 9 (Leu242) have been shown as 
the substrate binding site (Barak et al., 2009; Lippert et al., 2007). The Cys125 and 
Cys157 residues play a key structural role in stability of the C-terminal domain 
(Hermann et al., 2005; Baryshev et al., 2006). The first is also important for the 
hydrophobicity of interdomain linker.  
Figure 1-3 Secondary structure of ERp29. The structure reveals an ER-targeting sequence 
at N-terminus and a variant of ER-retention motif at C-terminus. Figure was sourced with 
permission from Zhang D and Richardson DR: Endoplasmic reticulum protein 29 (ERp29): 
An emerging role in cancer. Int J Biochem Cell Biol. 43: 33-36.  
Size exclusion chromatography, cross-linking, and dynamic light scattering studies 
suggest oligomerization of ERp29 (Mkrtchian et al., 1998a; Ferrari et al., 1998). Its 
dimerization in particular is of importance and essential for its diverse functions. 
ERp29 mutant that lose the ability to dimerize efficiently is unable to mediate 
Polyomavirus infection and thyroglobulin (Tg) secretion (Rainey-Barger et al., 2007). 
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The N-terminal domain exclusively mediates and is essential for the dimerization 
(Liepinsh et al., 2001). Mutagenesis study further revealed that residues Gly37, Leu 
39, Asp42, Lys48, and Lys52 contribute to the dimerization (Rainey-Barger et al., 
2007; Lippert et al., 2007). 
Consistent with the presence of ER-retention motif, ERp29 has been shown to 
localize in the luminal part of ER by biochemical and morphological analysis 
(Mkrtchian et al., 1998b). This localization however is not exclusive, as together with 
its substrate Tg ERp29 is co-secreted (Sargsyan et al., 2002b). Furthermore, ERp29 
was also identified in cytoplasmic lipid droplets (CLD) produced during lactation (Wu 
et al., 2000). Tissue staining revealed presence of ERp29 in nuclei in tumor and 
control cells (Cheretis et al., 2006). The significance of this localization is not yet 
clear.   
Compare to most ER proteins, ERp29 is unique as it does not have the expected 
post-translational modifications and ATP-dependent properties (Ferrari et al., 1998). 
In addition, calcium binding motif and ER-stress response element that can be found 
in other reticuloplasmins are absent in ERp29 (Demmer et al., 1997). Therefore, 
despite structural similarities with other proteins, such as PDIs and Windbeutel, 
ERp29 may have different, while complementary, functions to other PDI-like proteins 
within ER system. 
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1.3.2 Functions 
In eukaryotic cells, ER functions in the production of secretory proteins and calcium 
regulations (Brodsky et al., 1997; Dorner et al., 1990). Serving these vital roles are 
reticuloplasmins such as PDIs, Binding Protein (BiP), calreticulin, and endoplasmin. 
These proteins have overlapping tasks such as protein-folding assistants and calcium 
buffers. Lack of calcium binding and double-cysteine motifs precludes ERp29 as 
calcium buffer and disulphide isomerase, leaving it as a possible protein-folding 
assistant. A distinct role of ERp29 in secretory events is implied by its high expression 
in secretory tissues (Hubbard et al., 2000b; Shnyder et al., 2000), inducibility under 
ER-stress condition (Mkrtchian et al., 1998b), PDI-like cellular expression profile and 
BiP-like predominant location in the rough ER (Shnyder et al., 2000), as well as 
colocalization with other ER-chaperones (Mkrtchian et al., 1998b). Furthermore, 
ERp29 is only found in multicellular organism where protein export function is 
extensively developed (Sargsyan et al., 2002a). 
ERp29 has been implicated in the production and/or secretion of various proteins 
including thyroglobulin, connexin 34, as well as soluble milk proteins (Baryshev et al., 
2006; Das et al., 2009; Mkrtchian et al., 2006). In addition it is known to regulate the 
ER membrane penetration during Polyomavirus infection, sperm maturation, as well 
as production of endomembrane proteins (Magnuson et al., 2005; Ying et al., 2010; 
MacLeod et al., 2004). 
ERp29 is also involved in the ER-stress response which triggers an unfolded protein 
response (UPR) characterized by transcriptional induction of genes that enhance 
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protein folding capacity and general translational attenuation to reduce protein load in 
the ER (Mkrtchian et al., 1998b). Since ERp29 lacks the ER stress response element, 
ER-stress induced ERp29 is thought to be regulated via XBP1/IRE1 pathway 
(Mkrtchian et al., 1998a; Bambang et al., 2009a). X-binding protein-1 (XBP1) is a 
key regulator of UPR that works by binding to DNA element other than ER-stress 
response element. It has been reported that XBP1 and p38 negatively regulates ERp29 
expression, while overexpression of ERp29 activates XBP1 (Bambang et al., 2009a; 
Zhang et al., 2010a).  
1.3.3 ERp29 in cancer development 
During carcinogenesis, physiological and/or pathological stimuli such as 
nutrient-depletion, oxidative stress, DNA-damage, calcium-deprivation, growth 
factors and oncogenic factors, have been shown to perturb ER homeostasis. Under 
these conditions, the unfolded/misfolded proteins accumulate, leading to ER stress 
and the activation of ER-specific signalling pathways (reviewed in Ron et al., 2007). 
Therefore, it is not surprising that major reticuloplasmins such as BiP and PDI are 
established key players in cancer development. The first is an attractive target for 
cancer therapy due to its role in protein production and survival of cellular stress 
while the later is proposed as biomarker due to its broad overexpression (Ma et al., 
2004; Ma et al., 1997). Consequently, efforts have been devoted to elucidate role of 
ERp29, a novel reticuloplasmin, in cancer development. However, conflicting results 
have emerged, implicating ERp29 as both oncogene and tumor suppressor. Table 1-2 
summarizes the findings of Erps29’s expression and role in carcinogenesis. 
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ERp29 as oncogene ERp29 as tumor supressor
ERp29 is upregulated in epithelial tumors  
(mammary, salivary, bladder, prostate, 
ovary, kidney, skin) (Shnyder et al. , 2008).
ERp29 is downregulated in pancreatic 
cancer (Lu et al. , 2004).
Direct relationship of ERp29 and tumor 
prognosis in basal cell carcinoma of the skin 
and ovarian tumor (Cheretis et al. , 2006; 
Bengsston et al. , 2007).
Inverse relationship of ERp29 and tumor 
prognosis in lung and colon cancer (Shnyder 
et al. , 2008).
Overexpression of ERp29 in endometrial 
and breast cancer (Mkrtchian et al. , 2008).
ERp29 is downregulated in breast cancer 
samples and is inversely regulated with 
cancer grade/stage (Bambang et al. , 
2009b). 
Cancer cell lines SK-N-SH, A549, A375, 
MCF7, and Hela express ERp29 (Myung 
et al. , 2004). 
Cancer cell lines Saos2, CaOv3, HCT116, 
HL60 and A673 do not express ERp29 
(Myung et al. , 2004). 
Dominant negative and silencing of ERp29 in 
MCF7 breast cancer cell line results in size-
reduction of tumor xenografts (Mkrtchian et 
al. , 2008).
Overexpression of ERp29 in MDA-MB231 
breast cancer cell line results in size-
reduction of tumor xenografts  (Bambang et 
al. , 2009b).  
Table 1-2 Studies on the relationship of ERp29 and cancer development. The left column 
summarizes those that support the idea that ERp29 is oncoprotein, the right column suggests 
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1.4 Rationale of work  
The ubiquitous and conserved expression of ERp29 suggests that it is imperative in 
basic cell functions. Thus, coupled with the importance of many reticuloplasmins in 
carcinogenesis, dysregulation of ERp29 might also contribute to tumor progression. 
Preliminary studies conducted were mainly focused on the associations of ERp29 
expression level and status and/or stage of cancer which revealed that ERp29 is 
differentially expressed in various cancers. There was, however, lack of effort to 
unravel how ERp29 functions in carcinogenesis. This prompted initiation of current 
study where overexpression of ERp29 in breast cancer cells was employed to 
elucidate the role of ERp29 in breast cancer progression.  
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Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Cell Lines 
All cell lines used in this research project were purchased from the American Type 
Culture Collection (ATCC, VA, USA). The metastatic MDA-MB231 and BT439 
breast cancer cell lines were grown in Dulbecco’s modified eagle medium (DMEM, 
Sigma, USA) and RPMI-1640 (GIBCO®, USA) respectively, supplemented with 10% 
fetal bovine serum (FBS; GIBCO®, USA). The ERp29-transfected MDA-MB231 and 
BT549 clones, as well as the vector-transfected control cells, were maintained in their 
respective media with 1mg/ml or 2mg/ml of G418 (Invitrogen, Oregon, USA) 
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2.1.2 Antibodies 
Primary antibodies used in this research project along with the dilution for 





aPKC Cell Signaling Technology (MA, USA) 1:1000 1:200 
β-actin Sigma (MO, USA) 1:10000 - 
β-catenin Cell Signaling Technology (MA, USA) 1:1000 1:200 
ERp29 (Acris, Hiddenhayse, Germany) 1:2500 1:500 
E-cadherin BD Biosciences PharMingen (CA, USA) 1:2500 1:500 
Fibronectin Cell Signaling Technology (MA, USA) 1:500 1:100 
pMLC Cell Signaling Technology (MA, USA) 1:1000 1:200 
Par3 Novus Biological (CO, USA) 1:1000 1:200 
Par6 Novus Biological (CO, USA) 1:1000 1:200 
Scribble Millipore (CA, USA) 1:500 1:100 
SNAI1 Abnova (Taipei, Taiwan) 1:200 1:50 
SNAI2 Abnova (Taipei, Taiwan) 1:200 1:50 
TCF3 Abnova (Taipei, Taiwan) 1:1000 1:200 
Twist Cell Signaling Technology (MA, USA) 1:1000 1:200 
Vimentin Millipore (CA, USA) 1:5000 1:1000 
ZEB1 Abnova (Taipei, Taiwan) 1:2500 1:500 
ZEB2 Abnova (Taipei, Taiwan) 1:1000 1:200 
ZO1 Cell Signaling Technology (MA, USA) 1:1000 1:200 
Table 2-1 List of primary antibodies. 
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2.1.3 Primers 
All the primers used were synthesized by 1st
Gene 
 BASE (Singapore). Table 2-2 represents 
the sequence for each primer.  
Primer sequence 
aPKC 
Forward 5’- TACGGCCAGGAGATACAACC - 3’ 






Reverse 5’-TATTGCTCGGCCCACTTCTTCTGA -3' 
Par3 
Forward 5’- GCAGTGTTTGATGAGCAGGA - 3’ 
Reverse 5’- TTGCTCGAAGGACTGAAGGT - 3’ 
Par6 
Forward 5’- GTTGCCAACAGCCATAACCT - 3’ 
Reverse 5’- CAGGTCACTGCTGTCATCGT - 3’ 
Scribble 
Forward 5’- CGCAAGGACACACCTCACTA - 3’ 
Reverse 5’- CCTCCTCCTGAGGACTACCC - 3’ 
SNAI1 
Forward 5’- CTGCAGGACTCTAATCCAG - 3’ 















Reverse 5'- CTGGACCATCTACAGAGGCTTGTA-3' 
ZO-1 
Forward 5’- TGGTGTCCTACCTAATTCAACTCA - 3’ 
Reverse 5’- CGCCAGCTACAAATATTCCAACA - 3’ 
Table 2-2 List of primer sequence. 
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2.2 Methods 
2.2.1 Construction of ERp29-expression vector 
The full length cDNA of human ERp29 gene was amplified by PCR with the Platinum 
High Fidelity Taq DNA polymerase (Invitrogen, Oregon, USA) using the forward 
primer (5-ATATGAATTCATGGCTGCCGCTGTGC-3’with EcoRI site underlined) 
and the reverse primer (5’-TCAGGATCCCTACAGCTCCTCCTCTTT-3’with BamHI 
site underlined). The PCR product was digested with BamHI and EcoRI and then 
cloned into BamHI and EcoRI sites of pcDNA3.1 (+) vector (Invitrogen, Oregon, 
USA) to form expression vector pcDNA-ERp29. The authenticity of ERp29 gene 
sequence was confirmed by DNA sequencing (primers used are listed in Table 2-2). 
2.2.2 Generation of ERp29-overexpressing single stable clones in MDA-MB231 
and BT549 breast cancer cells 
To create ERp29-overexpressing clones, ERp29-pcDNA3.1 vector obtained above 
was used to transfect MDA-MB231 and BT549 cells. The empty vector (pcDNA3.1) 
served as control. Cells were seeded in a 6-well plate to a confluency of 60-70%. For 
each well, 1μg of plasmid vector was diluted in the appropriate amount of 
Opti-MEM®I reduced serum medium (Invitrogen, Oregon, USA) and the cells were 
transfected using LipofectAMINETM 2000 (Invitrogen, CA, USA), according to the 
manufacturer’s instructions. Two days after the transfection, selecting agent G418 was 
added to select for successful transfectants. For single clone generation, serial 
dilutions were performed to obtain single cells. Each colony produced from these 
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single cells was verified for their ERp29 expression using reverse-transcription PCR 
and immunoblot assay. Two ERp29-overexpressing clones for MDA-MB231 (clone B 
and E) and for BT549 (clone A and K) were used in subsequent experiments. 
2.2.3 RNA extraction and reverse-transcription polymerase chain reaction 
(RT-PCR) 
Total RNA from cultured cells was extracted using NucleoSpin® RNA II kit 
(Macherey-Nagel GmbH & Co. KG, Germany) according to the manufacturer’s 
protocol. Briefly, 5x106
0.5μg of purified RNA template was used to synthesize first strand cDNA using 
ImProm-II reverse transcriptase (Promega, WI, USA). This reverse transcription was 
performed at 42°C for 1h, followed by 70°C for 15min. The cDNA was then 
amplified by semi-quantitative PCR using respective specific primers (Table 2-2). 
This amplification was carried out as shown in Table 2-3 using Thermal Cycler 
GeneAmp®PCR System 9600 (Applied Biosystems, CA, USA).  
 cells were trypsinized, washed, pelleted and subsequently 
lysed in lysis buffer containing β-mercaptoethanol. The lysate was then filtered and 
passed through the provided NucleoSpin® RNA II Column for RNA binding followed 
by DNA digestion. Purified RNA was eluted and its concentration was determined 
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Steps Temperature (°C) Time 
1. Initializing 94 5min 
2. Denaturation 94 30s 
3. Annealing According to sequence of primer 30s 
4. Extension/elongation 72 30s 
5. Final elongation 72 7min 
6. Final hold 4  ~ 
Table 2-3 PCR amplification steps. *30 cycles (Steps 2-4) 
Amplified DNA was finally run on 1% DNA agarose gel (Seakem®LE Agarose, 
Cambrex Bio Science Rockland, Inc., Rockland, ME, USA) containing 0.1μg/ml 
Ethidium Bromide at 90V for 40 min. Fluorescence signal was captured with the 
MULTI GENIUS BioImaging System (Syngene, Frederick, MD, USA). The level of 
β-actin served as the loading control. 
2.2.4 Protein extraction and immunoblot/western blot assay 
To prepare total cell lysate, cells were trypsinized and washed once with 
phosphate-buffered saline (PBS, pH 7.4). The cells were then resuspended in cold 
RIPA buffer (1% Igepal, 1% sodium deoxycholate, 0.15M sodium chloride, 0.01M 
sodium phosphate, pH 7.2, and 2mM EDTA) supplemented with protease inhibitors 
(Roche Diagnostics, Indianapolis, IN) and phosphatase cocktail inhibitors I and II 
(1:100; Sigma-Aldrich, Steinheim, Germany), and kept on ice for 2hr to ensure total 
lysis. Cell lysate was then centrifuged at 4°C and the supernatant was collected. 
Protein concentration was determined using the Coomassie Plus Bradford assay 
(Pierce, Rockford, IL). 
Depending on the size and relative expression of each protein tested, 15 to 75μg of 
total proteins was separated on 8-12% SDS-PAGE gels using Mini-PROTEAN 3 
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Electrophoresis Cells (Bio-Rad, Hercules, CA, USA) at 70V for 30min followed by 
100V until protein of interest is separated well. The proteins were then transferred 
onto Hybond-P Polyvinylidene Fluoride (PVDF) membrane (GE Healthcare, Uppsala, 
Sweden) using the wet transfer apparatus (Bio-Rad, Hercules, CA, USA) at 110V for 
at least 1hr. The membrane was blocked with 5% non-fat milk (Santa Cruz 
Biotechnology, Inc., CA, USA) in Tris-buffered saline containing 0.1% Tween-20 
(TBST) and incubated overnight with appropriate primary antibodies at 4ºC. Upon 
washing, secondary antibodies - HRP-conjugated goat anti mouse IgG (Molecular 
Probes, Invitrogen, Oregon, USA) at 1:5000 or HRP-conjugated goat anti rabbit IgG 
(ZYMED® Laboratories, Inc. San Francisco, CA, USA) at 1: 10,000 or 
HRP-conjugated rabbit anti goat IgG (Molecular Probes, Invitrogen, Oregon, USA) at 
1:5000 - were applied for 1h at room temperature. The chemiluminescent signals were 
visualized using SuperSignal West Pico Chemiluminescent Substrate (Pierce, 
Rockford, IL, USA) and captured with the MULTI GENIUS BioImaging System 
(Syngene, Frederick, MD, USA). Signal intensity was analyzed by the GeneTools 
software (Syngene, Frederick, MD, USA). The level of β-actin was used as the 
loading control. 
2.2.5 Immunofluorescence and confocal microscopy 
Cells were plated onto 12mm glass coverslips and incubated overnight at 37°C in a 
humidified 5% CO2 incubator to allow attachment. The following day, cells were 
rinsed twice in PBS and fixed with 4% paraformaldehyde (Sigma-Aldrich, Steinheim, 
Germany) for 15mins and permeabilized with 0.1% Triton X-100 for 10mins. This 
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was followed with blocking in 3% BSA for 1hr at room temperature and overnight 
incubation in primary antibody at 4°C. Upon washing with PBS containing 0.02% 
Tween-20 (PBST), cells were incubated for 1hr at room temperature with anti-mouse 
Alexa Fluor® 488 goat anti-mouse IgG (1:1000; Invitrogen, CA, USA) or Alexa 
Fluor® 532 goat anti-rabbit IgG (1:1000; Invitrogen, CA, USA). To visualize actin 
filaments, cells were stained with rhodamine-phalloidin (1:500, Invitrogen, Oregon, 
USA) for 45min at 37ºC. After final washes with PBS, the coverslips were mounted 
using the antifade mounting fluid containing DAPI (Vector Laboratories, Inc, CA, 
USA) and the images were examined and captured using Olympus Fluoview FV500 
confocal laser scanning microscope (Olympus, Japan). Raw images were analyzed 
using Olympus FV10-ASW 1.7 Viewer software (Olympus, Japan). 
2.2.6 Cell proliferation assay 
Cells (1x103 per well) were seeded in triplicate in 96-well culture plates and cultured 
for 4 days at 37°C in a humidified 5% CO2 atmosphere. Viable cells were quantified 
at 24hr interval using CellTiter 96® AQueous
2.2.7 Cell cycle assay 
 One Solution Cell Proliferation Assay 
(Promega, WI, USA). The absorbance at 492nm was measured using an Infinite F200 
microplate reader (TECAN Austria GmbH, Grodig, Austria). 
Cells were starved for 24hr and released from starvation for another 24hr. Following 
that, cells were washed twice in ice-cold PBS and fixed in 75% ethanol on ice for 2hr. 
The cells were then washed twice in PBS and stained with PI solution (50µg/ml 
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propidium iodide (Invitrogen, Oregon, USA), 3.8mM sodium citrate, 0.5mg/ml 
RNase A) at room temperature for 30mins. DNA profile was analyzed using a flow 
cytometer (CyAn ADP Analyzer, Dako, Glostrup, Denmark). Cell cycle data analysis 
was performed by using the SummitTM
2.2.8 Cell migration assay 
 software (Dako, Glostrup, Denmark). 
Quantitative cell migration was measured using CytoselectTM cell migration assay kit 
(Cell Biolabs, Inc, San Diego, CA, USA) according to manufacturer’s protocol. 
Briefly, cells were serum starved for 24hr, harvested and seeded (7.5x105
2.2.9 Cell invasion assay 
cells/ml) in 
triplicate in the upper chambers of the inserts. The inserts were then transferred into 
wells containing media with 10% of the chemoattractant, FBS and incubated for 20hr 
at 37°C. Migratory cells passed through polycarbonate membrane and clinged to the 
bottom side, while non-migratory cells stayed in the upper chamber. Upon removal of 
the later, migratory cells were stained and quantified at 570nm using Infinite F200 
microplate reader. 
Cell invasion assay was assessed using QCMTM 24-Well Cell Invasion Assay 
(Chemicon International, Temecula, CA, USA) with an 8 mm pore size according to 
the manufacturer’s instructions. Briefly, cells were serum starved for 24h and 
harvested. Equal number of cells (7.5x105cells/ml) were seeded in triplicate onto the 
top chamber of the inserts and incubated at 37°C in a humidified 5% CO2 atmosphere 
for 24h, with 10% FBS in the lower chamber. The cell suspension was then aspirated 
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while invading cells that had migrated through and attached to the bottom of 
membrane were then dissociated from membrane in cell detachment buffer. Cells 
were subsequently lysed and detected by CyQuant GR®
2.2.10 Statistical analysis 
 dye. Fluorescence reading 
was taken at 485/535nm (Ex/Em) with Infinite F200 microplate reader. 
All cell culture experiments were performed at least three times independently. Data 
for functional assays was presented as mean±SD as indicated. One-way analysis of 
variance or Student t-test was used to analyze the significance of differences. 
Two-tailed p<0.05 was considered significant. 
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Chapter 3: Results 
3.1 Generation of ERp29-overexpressing MDA-MB231 and BT549 single 
stable clones 
Gene transfection is one of the most utilized methods in unraveling protein functions. 
Thus, to elucidate the role of ERp29 in breast cancer progression, MDA-MB231 and 
BT549 breast cancer cells were stably-transfected with full-length of human ERp29 
gene as described in Material and Methods. Upon isolation of single clones, the 
effectiveness of ERp29-transfection was verified by RT-PCR, immunoblot, as well as 
immunofluorescence assays (Figure 3-1 A, B, and C). Of the clones generated, two 
ERp29-overexpressing clones from each cell line were chosen for further experiments 
(Clone B and E for MDA-MB231, clone A and K for BT549). For simplification, the 
clones will be termed MDA-MB231/Ctrl, MDA-MB231/B, MDA-MB231/E, as well 
as BT549/Ctrl, BT549/A, BT549/K. Using β-actin as loading control, expression of 
ERp29 protein level revealed 3.2- and 4.6-fold of increase in MDA-MB231/B and 
MDA-MB231/E as well as 3.8- and 3.6-fold of increase in BT549/A and BT549/K 
compared to their control counterparts (Figure 3-1 B). 
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Figure 3-1 Expression of ERp29 in ERp29-transfected MDA-MB231 and BT549 cells. 
ERp29 expression in selected single stable clones was examined at mRNA (A) and protein 
level (B) by RT-PCR and immunoblot respectively. β-actin was used as loading control. 
Observations from immunofluorescence assay were in agreement with the immunoblot results 
(C). 4’,6-diamidino- 2-phenylindole (DAPI-blue staining) was used to visualize DNA. (60× 
magnification) 
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3.2 Overexpression of ERp29 induces MET-morphological changes in 
MDA-MB231 and BT549 breast cancer cells 
3.2.1 ERp29-overexpressing clones exhibit epithelial morphology 
Upon isolation of single stable clones, significant morphological changes were 
observed in ERp29-overexpressing cells generated from both MDA-MB231 and 
BT549 cell lines. MDA-MB231/Ctrl exhibited mesenchymal-like morphology; 
elongated appearance, loose cell-cell contacts, and spreading morphology (Figure 3-2 
A, top panel). In contrast, MDA-MB231/B and MDA-MB231/E, which often grew in 
clusters, displayed cobblestone appearance accompanied by increased cell-cell 
contacts. In addition, the actin cytoskeletal organization visualized by phalloidin 
staining demonstrated a change from filamentous stress fiber arrangement in control 
cells to cortical actin formation in ERp29 overexpressing MDA-MB231 clones 
(Figure 3-2 A, bottom panel). In agreement with the observed reduction of stress fiber, 
immunoblot and immunofluorescence assays performed showed decreased level of 
phosphorylated myosin light chain (pMLC) in MDA-MB231/B and MDA-MB231/E 
compared to the control (Figure 3-2 B and C). Phosphorylation of MLC by ROCK, a 
Rho-activated kinase downstream of RhoA activation, is necessary for the formation 
and maintenance of stress fiber (Sanders et al., 1999). 
Similarly, upon ERp29-transfection the morphology of BT549 cells was altered. 
BT549/Ctrl had elongated spindle-like appearance characteristic of basal-like cells, 
while BT549/A and BT549/K showed a more epithelial morphology indicated by 
compact organization (Figure 3-2 A, top panel). It should be noted that the extent of 
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ERp29-induced morphological change was more prominent in MDA-MB231 than 
what was observed in BT549 cells. Further inspection on the cytoskeletal organization 
also demonstrated a change from filamentous stress fiber to cortical actin formation 
(Figure 3-2 A, bottom panel). In accordance, level of pMLC was reduced in 
ERp29-overexpressing BT549 clones compared to their control counterpart (Figure 
3-2 B and C). Akin to the degree of morphological changes, the pMLC reduction was 
more apparent in ERp29-overexpressing MDA-MB231 clones than in 
ERp29-overexpressing BT549 clones.  
Taken together these results suggest that overexpression of ERp29 induces reversion 
of mesenchymal MDA-MB231 and basal-like BT549 breast cancer cells to a 
phenotype that resembles epithelial cells, which is reminiscent of morphological 













         
Figure 3-2 Morphological changes and cytoskeletal actin rearrangement in 
ERp29-overexpressing MDA-MB231 and BT549 clones. (A) Top panel: comparison of 
morphological changes between control cells and ERp29-overexpressing clones under phase 
contrast microscope (60× magnification). Bottom panel: cytoskeletal actin remodeling from 
stress fiber to submembranous cortical actin as visualized by rhodamine phalloidin staining 
(120X magnification). (B) Immunofluorescence examined the decrease in phosphorylation of 
MLC (green), consistent with the observed reduction of stress fiber formation (60X 
magnification). (C) Verification of pMLC level by immunoblot was in agreement with 
immunofluorescence assay. β-actin was used as loading control. 
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3.2.2 Overexpression of ERp29 restrores tight junctions and cell polarization 
Epithelial morphology is maintained by proteins involved in cell-cell junctions and 
cell polarization. Therefore, expression of members of tight junctions and polarity 
complexes were examined by RT-PCR and immunoblot. In addition, 
immunofluoresence assay was performed to analyze their cellular distribution and 
expression. 
Both apical polarity complexes, Par and Crumbs, are important in recognizing initial 
polarization cues and establishment of junctional complexes. However, Par 
complex-associated proteins (Par3, Par6, aPKC) were chosen to be investigated as 
compared to Crumbs, since Par complex is involved in broader range of cell types and 
regulates more diverse polarity-related cellular events (Wang et al., 2007). 
Additionally, Scribble (care-taker of the basolateral identity in cell polarization) as 
well as ZO1 (marker of tight junctions development) were also examined.  
Initial work by RT-PCR revealed that all of the genes tested remain significantly 
unchanged at transcriptional level both in MDA-MB231 and BT549 models (Figure 
3-3 A). Figure 3-3 B however, shows that compared to the control cells, there was an 
increase of protein level of Par3 and Scribble in ERp29-overexpressing MDA-MB231 
and BT549 clones, indicating post-transcriptional regulation of these proteins. The 
level of Par6 and aPKC remained significantly unaltered.  
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Figure 3-3 Overexpression of ERp29 regulated tight junction and polarity proteins at 
protein level. (A) mRNA level of all the investigated proteins remained unchanged. (B) 
Protein expression of Par3 and Scribble was increased in ERp29-overexpressing 
MDA-MB231 and BT549, but that of Par6, and aPKC was unaltered. β-actin was used a 
loading control. 
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Par3 is known as one of the early signal in the establishment of apical-basal polarity 
(reviewed in Godde et al., 2010). Initiation cues induce its proper relocalization where 
it then promotes separation of apical and basal polarity complexes as well as 
enrichment of cell-cell junction modulators. Figure 3-4 A shows that while Par3 
exhibited diffused expression in MDA-MB231/Ctrl, it was localized at cell-cell 
contact sites in MDA-MB231/B and MDA-MB231/E, indicating its functional state. 
In contrast, there was no change in localization of Par6 and aPKC. Basal polarity 
protein Scribble was also properly localized in ERp29-overexpressing MDA-MB231 
clones (Figure 3-4 A). As mentioned earlier, formation of tight junctions is often 
considered as the final step of MET (Lee et al., 2006). Thus membranous staining of 
ZO1 suggests that MDA-MB231/B and MDA-MB231/E has undergone full MET and 
completed cell polarity program. This proposal, however, must be considered with 
care as in carcinogenesis sequential order of developmental EMT/MET is often not 
followed closely.  
In ERp29-overexpressing BT549 clones, similar membrane redistribution of Scribble, 
as in ERp29-overexpressing MDA-MB231 clones, was observed (Figure 3-4 B). 
However, ZO1 and Par3 seemed to be affected in lesser extent. Instead of continuous 
staining, ZO1 in BT549/A and BT549/K showed spot-like nascent tight junctions. 
Similarly, the expression of Par3 in ERp29-overexpressing BT549 clones was 
detected only in some of the cell-cell contact sites (indicated by white arrows). 
Similar to MDA-MB231 model, distribution of other Par complex, Par6 and aPKC, 
remained unchanged in ERp29-overexpressing BT549 clones compared to the control 
Chapter 3: Results 
 41 
cells.  
While Par3 is known to function in the establishment of cell polarization, Scribble is 
believed to be involved in the maintenance of apical-basal polarity as well as cell 
junctions (Qin et al., 2005). Its downregulation in Madin-Darby Canine Kidney 
(MDCK) cells results in delay in ZO1 assembly (Qin et al., 2005). In both 
ERp29-overexpressing MDA-MB231 and BT549 clones, Scribble is properly 
localized at cell membrane (Figure 3-4). While this observation does not follow the 
sequential order of apical-basal polarity establishment, it supports that to certain 
degree that ERp29 does restore cell polarization. Furthermore, Scribble is a known 
tumor suppressor, which is targeted by E6 protein of human papillomavirus, a major 
cause of cervical cancer (Nakagawa et al., 2000). In breast cancer, Scribble is often 
downregulated or mislocalized, and it has been shown to inhibit breast cancer 
progression in MCF10A cells (Zhan et al., 2008). Therefore, it can be suggested that 
its upregulation contributes to in vivo tumor suppressing effect of ERp29 (Bambang et 
al., 2009b).  
Taken together, the observations of the phenotypic changes and the relocalization of 
junctional Par3, Scribble, and ZO1 in ERp29-overexpressing MDA-MB231 and 
BT549 clones indicate that these cells have undergone reversion to a phenotype that 
displays aspects of epithelial polarity, further supporting the notion of ERp29-induced 
morphologic MET. 
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Figure 3-4 Overexpression of ERp29 relocalized Par3, Scribble, and ZO1 to cell-cell 
contact sites. (A) Immunoflourescence assay showed strong localization of Par3, Scribble, 
and ZO1 at the cell-cell contact sites in MDA-MB231/B and MDA-MB231/E, while control 
cells displayed diffused pattern. DAPI was used to stain nucleus (blue) (60× magnification). 
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Cont’d Figure 3-4 Overexpression of ERp29 relocalized Par3, Scribble, and ZO1 to 
cell-cell contact sites. (B) Scribble showed a strong membranous staining in 
ERp29-overexpressing BT549 clones. Par3 and ZO1 were also detected in the cell periphery 
though with weaker signal (white arrows). DAPI was used to stain nucleus (blue) (60× 
magnification).  
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3.2.3 Overexpression of ERp29 inhibits cell proliferation 
Changes in cell shape are often associated with physiological alterations, including 
proliferative potential (Lu et al., 2001). To examine whether overexpression of ERp29 
regulates proliferation of MDA-MB231 and/or BT549 cells, cell growth assay over a 
four-day period was performed. Figure 3-5 A shows negative regulation of cell 
proliferation in ERp29-overexpressing MDA-MB231 clones compared to the control 
cells. This ERp29-induced inhibition of proliferation in MDA-MB231 is implicated in 
tumor growth suppression in vivo (Bambang et al., 2009b). Likewise, BT549/A and 
BT549/K grew at slower rate compared to BT549/Ctrl (Figure 3-5 B).   
        
Figure 3-5 Overexpression of ERp29 inhibited cell proliferation. Both 
ERp29-overexpressing MDA-MB231 (A) and BT549 clones (B) demonstrated slower 
proliferation rate compared to the control cells. Data shown represents the mean±SD of 
triplicate experiment. Bars, SD; **p<0.05. 
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The effect of cell morphology on proliferative potential is contributed by its influence 
on cell cycle control. Depending on the shape, cell may or may not be able to acquire 
signals from its environment to pass through cell cycle restriction point (Huang et al., 
1998). Cell spreading allows signals elicited by growth factors from the environment 
to pass through G1/S restriction point while compact morphology prevents growth 
factor access thereby inducing cell cycle arrest at G1/S.  
To learn if overexpression of ERp29 inhibits cell proliferation by regulating cell cycle 
progression, cell cycle profile was obtained for control and transfected-cells using 
propidium idodide which visualized DNA contents. Figure 3-6 A shows increase of 
G0/G1 population in ERp29-transfected MDA-MB231 compared to the control, 
indicating ERp29-induced cell cycle arrest at the stage. In accordance with this 
finding, further inspections revealed that cyclin-dependent kinase inhibitor 2B 
(CCKN2B, p15), a G1 checkpoint protein, was activated in MDA-MB231/B and 
MDA-MB231/E (Bambang et al., 2009b).  
Surprisingly, similar observations were not observed in the BT549 model. BT549/A 
and BT549/K had increased G2/M population compared to BT549/Ctrl implying 
G2/M arrest (Figure 3-4 B). This indicated that ERp29-transfected BT549 employed a 
different mechanism in regulating cell proliferation which warrants further 
investigations. In some cases, the ability to regulate morphology can be uncoupled 
form ability to modulate cell proliferation (Aranda et al., 2006). Therefore, this has to 
be taken under consideration in examining the nature of proliferation inhibition by 
ERp29.  
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Figure 3-6 Overexpression of ERp29 regulated cell cycle progression. Representative cell 
cycle profile of MDA-MB231/B and MDA-MB231/E (A), as well as BT549/A and BT549/K 
(B) with their respective controls. Note the increase of G0/G1 populations in 
ERp29-tranfected MDA-MB231 and G2/M populations in ERp29-transfected BT549.  
 
Thus far, the results suggest that overexpression of ERp29 in MDA-MB231 and 
BT549 breast cancer cells induces alterations in cell shape, reminiscent of 
morphological changes in MET, accompanied by inhibition of cell proliferation 
whose mechanisms might involve regulation of cell cycle progression.  
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3.3 Overexpression of ERp29 induces MET-molecular changes in MDA-MB231 
cells 
3.3.1 Regulation of EMT/MET markers. 
The finding that ERp29-overexpression in MDA-MB231 and BT549 cells resulted in 
morphological change led to the question whether or not the change is associated with 
molecular MET. Thus, the expression and localization of epithelial markers and 
mesenchymal markers were examined using immunoblot and immunofluorescence 
analysis. Expression of E-cadherin and cytokeratin-19 (CK19), the primary 
intermediate filament in mammary epithelial cells, was used as markers for epithelial 
phenotype; as well as expression and more importantly membranous localization of 
β-catenin. Expression of vimentin and fibronectin was employed as mesenchymal 
markers.  
As indicated in Figure 3-7 A (left panel), MDA-MB231/B and MDA/MB231/E 
showed an upregulated levels of epithelial markers (E-cadherin, CK19, and total 
β-catenin) and downregulated levels of mesenchymal markers (fibronectin and 
vimentin) compared to MDA-MB231/Ctrl. Further investigation revealed that the 
upregulated E-cadherin is functional as it was relocalized at cell membrane (Figure 
3-7 B, left panel). Overexpression of ERp29 also regulated intracellular distribution of 
β-catenin which is a determinant of cell fate (Figure 3-7 B, left panel). As mentioned 
earlier, β-catenin is a dual-function protein; membranous β-catenin mediates contact 
of E-cadherin and actin cytoskeleton while nuclear β-catenin binds to TCF/LEF and 
acts as transcription factor. This complex mediates Wnt signaling and is responsible 
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for cell proliferation, dedifferentiation, inhibition of apoptosis, and tumor progression 
by inducing EMT (Reva et al., 2005; van de Wetering et al., 2002; Fuchs et al., 2005). 
In contrast, reduction of β-catenin/TCF/LEF activity has been demonstrated to 
promote epithelial differentiation (van de Wetering et al., 2002). Thus, in addition to 
supporting the notion of molecular MET in ERp29-overexpressing MDA-MB231 
clones, relocalization of β-catenin from nucleus to cell membrane suggests that 
ERp29 signaling crosstalk to the Wnt signaling.  
Interestingly, similar observations were not found in the BT549 model (Figure 3-7 A 
and B, right panel). Overexpression of ERp29 did not regulate the expression and/or 
localization of E-cadherin, CK19, and vimentin, while expression of β-catenin was 
slightly reduced in BT549/A and BT549/K compared to BT549/Ctrl. It is worth 
noting that while overexpression of ERp29 did not change intracellular distribution of 
β-catenin in this cell line, localization of this protein was different in 
MDA-MB231/Ctrl and BT549/Ctrl (Figure 3-7 B). β-catenin is mainly localized in 
the nucleus in MDA-MB231 cells, whereas β-catenin staining is diffused in cytoplasm 
with slightly stronger membranous signal in BT549 cells. These suggest that β-catenin 
functions differently in the different cell lines; it does not mediate Wnt signaling in 
BT549 cells. It is also interesting to note that the mesenchymal marker fibronectin 
was significantly downregulated in ERp29-overexpressing BT549 clones compared to 
their control counterparts. Fibronectin is a component of extracellular matrix that is 
generated by mesenchymes and not epithelia. Its production enhances growth 
factor-induced EMT in primary human bronchial epithelial cells (Câmara et al., 2010). 
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Furthermore, the upregulation of fibronectin has been shown to be one of the early 
events in EMT without apparent reduction of E-cadherin, suggesting the existence of 
a separate mechanism regulating its expression (Lindley et al., 2010). The persistence 
of mesenchymal markers and failure to fully express epithelial markers in 
ERp29-overexpressing BT549 compared to MDA-MB231 clones suggests that BT549 
cells transfected with ERp29 still maintained some aspects of mesenchymal 
phenotype. Further investigations of other EMT markers, such as other cytokeratins, 
α-smooth muscle actin, are needed to determine the extent of the transition in 
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Figure 3-7 Profile of epithelial and mesenchymal markers in ERp29-overexpressing 
MDA-MB231 and BT549 clones. (A) Protein level of epithelial markers (E-cadherin, 
β-catenin, and CK19) and mesenchymal markers (vimentin and fibronectin) as examined by 
immunoblot. β-actin was used as loading control. (B) Immunofluorescence images revealed 
the localization of EMT/MET markers. DAPI staining (blue) indicated the nuclear staining. 
(60× magnification) 
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3.3.2 Regulation of E-cadherin repressors. 
Molecular alterations of MET are largely contributed by transcription factors that 
regulates EMT/MET markers, in particular E-cadherin. To investigate this, the 
kinetics of known E-cadherin regulators (SNAI1, SNAI2, ZEB1, ZEB2, TCF3, and 
Twist) were investigated by RT-PCR and immunoblot. In addition, 
immunofluorescence assay was performed to learn the localization of the regulators as 
their transcriptional activity also depends on subcelullar localization. For example, 
phosphorylation of SNAI1 by p21-activated kinase-1 (PAK1) results in nuclear 
accumulation of SNAI1 and subsequent transcriptional repression of target genes 
(Thiery et al., 2006). On the other hand, knockdown of PAK1 expression resulted in 
cytoplasmic accumulation of SNAI1 and ablation of its transcriptional-repressor 
activity. 
Concurrent with the upregulation of E-cadherin observed earlier, the transcription 
repressors SNAI1, SNAI2, ZEB2, and Twist were downregulated both at 
transcriptional and translational levels in ERp29-overexpressing MDA-MB231 clones 
compared to the control cells (Figure 3-8 A). RT-PCR and immunoblot revealed 
unchanged expression level of ZEB1, excluding its involvement in ERp29-mediated 
downregulation of E-cadherin in MDA-MB231 cells. Of note, there was no change in 
the localization of all of the transcription factors (Figure 3-9 left panel).   
Also in agreement with previous results, overexpression of ERp29 did not negatively 
regulate the level of any E-cadherin repressors in BT549 cells (Figure 3-8 B) nor did 
it change their localization (Figure 3-9, right panel). These suggested that SNAI1, 
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ZEB1, ZEB2, and Twist were not affected by ERp29-overexpression in BT549 cells. 
Furthermore there was an increase of SNAI2 protein but not its mRNA in BT549/A 
and BT549/K compared to BT549/Ctrl. Contrast to SNAI1, SNAI2 is more broadly 
expressed and in some cases its expression is unrelated to EMT (Barrallo-Gimeno et 
al., 2005). Due to its subnuclear localization, SNAI2 has been postulated to localize to 
target promoters, where activation occurs, to repress basal and activator-mediated 
transcription (Hemavathy et al., 2000). 
It is interesting to note that TCF3 was upregulated in both ERp29-overexpressing 
MDA-MB231 and BT549 clones. The upregulation was observed at both 
transcriptional and translational levels (Figure 3-8). Although the biochemical reason 
is unclear, this phenomenon is not unprecedented as there exist examples where 
E-cadherin repressors do not show inverse relation with E-cadherin levels (Rosivatz 
et.al., 2002; Conacci-Sorrell et.al., 2003). TCF3 has been shown to be downregulated 
in immortalized breast cells MCF10A undergoing spontaneous EMT, while SNAI2 
was upregulated (Sarrió et al., 2008).  
Taken together, the results suggest that downregulation of E-cadherin repressors is 
responsible, at least in part, for the molecular alterations of ERp29-induced molecular 
MET in MDA-MB231 cells.  
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Figure 3-8 Overexpression of ERp29 differently regulated E-cadherin repressors in 
MDA-MB231 and BT549 cells. (A) ERp29-overexpressing MDA-MB231 clones expressed 
lower level of SNAI1, SNAI2, ZEB2, and Twist at transcriptional (left panel) and 
translational level (right panel) compared to control cells; while expression of TCF3 was 
increased. β-actin was used as loading control.   
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Cont’d Figure 3-8 Overexpression of ERp29 differently regulated E-cadherin repressors 
in MDA-MB231 and BT549 cells. (B) Overexpression of ERp29 did not downregulate any 
of the E-cadherin repressors in BT549 cells. Note that in both ERp29-overexpressing 
MDA-MB231 and BT549 clones, transcriptional and translational level of TCF3 was 
upregulated. β-actin was used as loading control 
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Figure 3-9 Overexpression of ERp29 did not alter the localization of E-cadherin 
repressors.  Immunofluorescence analysis confirmed the dowregulation of SNAI1, SNAI2, 
ZEB2, and Twist in MDA-MB231/B and MDA-MB231/E compared to MDA-MB231/Ctrl. In 
addition, there was no relocalization of any of the E-cadherin repressors tested both in 
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3.4 Overexpression of ERp29 induces MET-behavioral changes in 
MDA-MB231 cells 
In addition to morphological and molecular alterations, MET also confers behavioral 
changes characterized by decrease in cell motility and invasiveness. Therefore, 
migration and invasion ability was examined in ERp29-overexpressing MDA-MB231 
and BT549 cells.  
Quantitative analysis using Transwell chamber showed a reduced motility in 
MDA-MB231/B and MDA-MB231/E compared to their control counterpart. Similar 
trend was also observed in the Matrigel invasion assay. As shown in Figure 3-10 A 
and B, both invasiveness and migration were reduced to less than 50% upon 
overexpression of ERp29. The cytoplasmic distribution of β-catenin and 
downregulation of SNAI1 might be accountable for this observation as nuclear 
localization of the first and expression of the second are known to regulate MMPs.  
Figure 3-10 C and D indicate that no significant change of neither migration nor 
invasion capacity was evident in ERp29-overexpressing BT549 clones compared to 
control cells. These observations were not unprecedented as behavioral change is 
closely associated with transcriptional reprogramming of EMT/MET which was not 
observed in this model (Figure 3-7 and 3-8 B). Downregulation of E-cadherin, in 
particular, is known to be essential for regulation of motility and invasiveness during 
EMT/MET (Maeda et al., 2005; Lindley et al., 2010). 
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Figure 3-10 Overexpression of ERp29 reduced motility and invasiveness of 
MDA-MB231 cells but not BT549 cells. Migration and invasion potential in 
ERp29-overexpressing MDA-MB231 (A, B) and BT549 clones (C, D) compared to control 
cells. Results were expressed as a mean of fold change from three independent results. Bars, 
SD; **p<0.05. 
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In summary, results presented here indicate that overexpression of ERp29 induced 
MET in both MDA-MB231 and BT549 cells. There are, however, discrepancies in the 
degree of ERp29-induced MET in the two models. In MDA-MB231 cells, 
overexpression of ERp29 results in complete MET characterised by all three aspects; 
morphological, molecular and behavioral. In contrast, overexpression of ERp29 in 
BT549 cells only confers morphological MET. In the next chapter, the novel finding 
of ERp29-induced MET in breast cancer cells will be discussed in greater details. 
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Chapter 4: Discussions 
Recently it has been reported that ERp29 expression is downregulated in breast 
tumors and is conversely related with breast cancer progression, suggesting a role of 
ERp29 as tumor suppressor (Bambang et al., 2009b). To address the functional 
contributions of ERp29 in breast cancer progression, MDA-MB231 and BT549 
invasive breast cancer cells, are transfected with full-length ERp29. In 
mesenchymal-like MDA-MB231 cells, overexpression of ERp29 results in complete 
MET characterized by changes in morphological (from mesenchymal to epithelial-like 
appearance), molecular (transcriptional regulation of EMT/MET markers), and 
behavioral changes (reduced capacity of migration and invasion). In basal-like BT549 
cells, ERp29 overexpression induces morphologic MET, which is similar to what 
happens in MDA-MB231 cells, is associated with cytoskeletal rearrangement and 
restoration of tight junctions and cell polarization. The change observed in 
ERp29-overexpressing BT549 cells is not accompanied by transcriptional and 
translational changes of E-cadherin, CK19, and vimentin, although fibronectin, one of 
the mesenchymal markers, is decreased. These data indicate the overexpression of 
ERp29 in BT549 cells led to incomplete MET.  
In this chapter, discussions will be focused on: (1) possible explanations for the 
discrepancies found in the two cell lines, (2) plausible mechanisms that lead to 
ERp29-induced MET, and (3) the contribution of this study in unraveling the 
functions of ERp29 especially in breast cancer progression.  
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4.1 Breast cancer cells: MDA-MB231 and BT549 
Early in the study, MDA-MB231 and MCF7 cells were used as models as they 
represent a typical mesenchymal and epithelial-like breast cancer cell lines 
respectively (Bambang et al. 2009b, Zhang et al. 2010). Further investigations 
revealed that overexpression of ERp29 altered the morphology of MDA-MB231 but 
not MCF7 cells, which already exhibit epithelial appearance. Of note, MCF7 cells 
express higher level of ERp29 compared to MDA-MB231 cells (Bambang et al., 
2009b). In order to confirm and explore more of the finding, BT549 cell was chosen 
as it displays similar morphology as MDA-MB231 cell (i.e. fibroblast-like). BT549 is 
also an invasive breast cancer cell line that expresses comparable level of ERp29 as 
MDA-MB231 (Bambang et al., 2009b). Surprisingly, while ERp29 overexpression 
induces parallel morphological changes in BT549 and MDA-MB231 cells, the 
molecular mechanisms are rather different. 
Cell lines are widely used to investigate tumor formation and progression, indeed a 
considerable part of our knowledge on breast carcinomas is based on in vivo and in 
vitro studies performed with breast cancer cell lines. Based on the phenotype and 
invasiveness - thus supporting the idea of EMT in breast cancer progression - breast 
cancer cell lines can be classified into three groups (Lacroix et al., 2004). The first 
includes luminal epithelial-like cells (e.g. MCF7) that express high level of epithelial 
markers, grow as cluster of polygonal cells with low invasive potential. The second 
group includes the weak luminal epithelial-like cells which express reduced amount 
of epithelial markers and grow in clusters of loosely attached cells. The last is 
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mesenhycmal-like group which expresses mesenchymal instead of epithelial markers, 
has fibroblastoid morphology, and is highly invasive. MDA-MB231 and BT549 cells 
are classified under the third group. In fact, microarray study showed that according 
to their gene expression pattern, both cell lines, as well as Hs578T, can be grouped 
together with primary breast stromal/fibroblast cell strain (HMS32) and an 
immortalised stromal cell line (UTSW) (Ross et al., 2001). Due to their 
aggressiveness, MDA-MB231 and BT549 are capable of forming tumor in vivo, 
therefore often used as models in study of breast cancer formation and metastasis. 
Despite the similarities, MDA-MB231 and BT549 cells exhibit many disparities. 
Firstly, BT549 cell line originates from primary papillary invasive ductal carcinoma 
while MDA-MB231 is derived from pleural effusion of invasive ductal carcinoma and 
has lost signatures of its origin tissue (Coutinho and Lasfargues, 1978 - unpublished 
data; Ross et al., 2001). The source of these cell lines may reflect their EMT status; 
the primary-origin of BT549 cells indicates that they are undergoing EMT, in contrast 
MDA-MB231 cells which has broken away from starting tumor may have undergone 
complete EMT. Study on ovarian carcinoma has shown that EMT/MET modulators, 
such as E-cadherin, SNAI1, SNAI2, and ZEB2 are differentially expressed in 
effusions compared to primary tumors (Elloul et al., 2010). This difference in extent 
of EMT may explain the observed molecular and biological variances in 
ERp29-induced MET between MDA-MB231 and BT549 cells. 
Additionally, BT549 cells are known to express higher level of N-cadherin (a 
cadherin-switch component implicated in molecular/behavioral EMT/MET) compared 
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to MDA-MB231 cells which express, if at all, very low level of N-cadherin (Iwatsuki 
et al., 2010). This discrepancy in N-cadherin expression may also explain different 
responds observed upon overexpression of ERp29. The expression of N-cadherin in 
epithelial-like PMC42-LA human breast cancer cells has been suggested to restrain 
EMT-like responses upon epidermal growth factor (EGF) induction (Ackland et al., 
2003).  
4.2 Complete and incomplete MET induced by ERp29  
Developmental EMT is a chronological process that follows strict series of events 
which are well defined and typically accompanied by cell fate decisions. On the other 
hand, pathological EMT associated with cancer typically lacks the coordinated and 
orderly induction of a complete EMT (reviewed in Gavert et al., 2008). The highly 
variable environmental cues coupled with genetic heterogeneity of the cancer may 
lead to varying degrees of epithelial plasticity and reactivation of developmental 
migratory programs. Thus, while cancer-EMT always involves morphological 
changes, the epithelial and mesenchymal marker regulations as well as migration and 
invasion capacity may differ widely. This is further complicated by the use of in vitro 
system which does not always allow epithelial cells to achieve full polarity. 
Nevertheless, in vitro cell culture based studies should not be underestimated as their 
simplicity has allowed relatively easy identification of many key players and 
mechanisms important in EMT/MET, including β-catenin and SNAI2 
(Conacci-Sorrell et al., 2003).  
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In this study, overexpression of ERp29 is shown to induce complete MET in 
MDA-MB231 cells and incomplete MET in BT549 cells. These suggest that there 
may be two different signaling pathways regulated by ERp29 in a context-dependent 
manner; one is associated with genetic reprogramming which results in 
molecular/behavioral alterations while the other regulates actin cytoskeleton, tight 
junctions, and polarity proteins resulting in morphological changes. In many systems, 
the induction of EMT involves upregulation of transcription factors (such as Snail, 
ZEB, and bHLH families) which regulate the expression of epithelial and 
mesenchymal markers as well as MMPs linking the molecular and behavioral aspects 
of EMT. These transcription factors are also known to regulate expression of tight 
junction and polarity modules; Snail family downregulates occludin and claudins as 
well as members of Crumbs complex; ZEB family downregulates ZO proteins 
(reviewed in Xu et al., 2009; Moreno-Bueno et al., 2008). There was, however, no 
change in the expression of mRNA level of any of the tight junction and polarity 
modules examined (Figure 3-3 A), thus excluding the involvement of transcriptional 
regulation of these proteins in ERp29-induced MET.  
Differential regulation of the morphological and molecular/behavioral aspects in 
EMT/MET has been observed in several studies. When epithelial nontransformed 
mouse mammary cell line NMuMG undergoes EMT upon addition of transforming 
growth factor-β (TGFβ), E-cadherin expression is not downregulated until day 3 of 
treatment, on the other hand the morphological change is evident from day 1 (Maeda 
et al., 2005). Similar to present study, the change in cell shape is accompanied by 
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changes of actin cytoskeleton, ZO1 localization, as well as fibronectin induction, all 
of which occur separately (i.e. earlier) than changes in E-cadherin expression and/or 
localization. Induction of EMT in human mammary epithelial cells (HMECs) also 
shows that loss of ZO1 and gain of fibronectin are early events (hours after induction) 
while loss of E-cadherin is only evident when morphological alterations have taken 
place (3 days after induction) (Lindley et al., 2010). It is interesting to note that in the 
two models, N-cadherin is differentially regulated. Compared to NMuMG/E9 cells 
where upregulation of N-cadherin is observed early, cadherin switch in HMECs is a 
late event. Unfortunately, lack of information on N-cadherin in present study prevents 
further investigation in regards to association of N-cadherin with morphologic and/or 
molecular MET.  
The observations described above propose that loss of E-cadherin, and possibly 
transcriptional regulation of other markers as well, is independently regulated from 
morphological changes during EMT/MET. Indeed, the study on NMuMG cells 
revealed that while cadherin switching is essential for behavioral changes, it is not 
required for the morphological alterations that accompany EMT (Maeda et al., 2005). 
When the upregulated N-cadherin in TGFβ-induced EMT is depleted by siRNA 
treatment, morphological change is still observed. In contrast, depletion of N-cadherin 
in these EMT cells results in slower migrating cells. The same phenomenon is also 
observed in immortalized breast cells, MCF10A (Maeda et al., 2005). 
In agreement with studies described earlier, present study suggests that 
overexpression of ERp29 independently modulates two pathways leading to induction 
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of MET. The morphologic MET is activated in both MDA-MB231 and BT549 cells 
while the molecular/behavioral MET is only active in MDA-MB231 cells.  
4.3 Associations with TGFβ-induced EMT 
The proposal that ERp29 regulates different downstream routes in the induction of 
MET is reminiscent of the activation of various pathways in growth factor-induced 
EMT, in particular TGFβ. TGFβ is a ubiquitously expressed cytokine that is closely 
associated with the carcinogenesis. Early in tumor progression, TGFβ acts as tumor 
suppressor by inducing apoptosis and cell cycle arrests. Once tumor cells acquire the 
resistance for the growth-inhibitory effect (i.e. in later stage of carcinogenesis), TGFβ 
may promote invasion and metastasis by inducing EMT (Oft et al., 1996). In fact, 
TGFβ is the most potent and well studied amongst other EMT inducers. TGFβ signals 
through two transmembrane kinase receptors, transforming growth factor-β receptor I 
(TβRI) and transforming growth factor-β receptor II (TβRII) (Feng et al., 2005). 
Ligand binding to TβRII promotes the recruitment and phosphorylation of TβRI 
which will phosphorylate downstream effectors. In general, there are two pathways 
through which TGFβ can induce EMT, the canonical Smad-dependent pathway and 
the non-canonical Smad-independent pathway.  
In the canonical pathway, activated TβRI phosphorylates Smad2 and Smad3 which 
will form a complex with Smad4. Together they translocate into the nucleus where 
they interact with DNA binding partners and regulate expression of various genes, 
among which are the EMT inducing factors (Işeri et al., 2011). Therefore, the 
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canonical pathway is often considered as gene expression/transcriptional-dependent 
pathway, contributing to the molecular changes in EMT. This pathway might be 
associated with ERp29-induced molecular/behavioral MET.  
The non-canonical TGFβ signaling takes place through its ability to stimulate various 
alternative pathways such as small GTP-binding proteins (Ras, Rho, and Rac1); 
phosphoinositide-3- kinase (PI3K), AKT, and mTOR; MAP kinases (p38 MAPK, 
ERK1/2, and JNK); Par6; NF-κB and Cox-2 (reviewed in Taylor et al., 2010). Of 
interest, TGFβ-induced EMT has also been shown to result in the downregulation of 
Par3 both at transcriptional and translational levels, leading to redistribution of Par6 
and aPKC from cell membrane (Wang et al., 2008). Since present study shows that 
overexpression of ERp29 does not alter mRNA level of Par3, this pathway will not be 
discussed further.  
Two of the non-canonical pathways are of interest in this study as they regulate 
polarity and tight junction proteins as well as actin cytoskeleton organization, thus 
contribute to morphological aspect of EMT. The first involves polarity module Par6. 
Par6 has been demonstrated to play a role in TGFβ-induced EMT by mediating the 
dissolutions of tight junctions (Ozdamar et al., 2005). Upon ligand binding, TβRII is 
recruited to tight junctions where TβRI and Par6 colocalize. This allows the 
phosphorylation of Par6 which leads to recruitment of Smurf1. Smurf1 promotes 
degradation of RhoA resulting in the dissolutions of tight junctions and therefore EMT. 
This pathway is independent of Smad as expression of non-phosphorylatable mutant 
version of Par6 does not block the Smad-mediated transcriptional activation of 
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vimentin gene expression (Ozdamar et al., 2005). Involvement of polarity and tight 
junction proteins in this model is an attractive feature in describing ERp29-induced 
MET. The absence of changes in Par6 expression, however, seems to suggest 
otherwise. It is worth noting that present study does not provide the phosphorylation 
status of Par6 upon ERp29 overexpression, warranting further investigations to 
confirm the hypothesis.  
In contrast to the Par6-mediated EMT that involves the degradation of RhoA, another 
non-canonical pathway results in activation of RhoA. The differential regulation of 
RhoA in TGFβ-induced EMT has been attributed to its downstream effectors. The 
capacity of RhoA to maintain tight junctions is believed to involve mDia, while 
ROCK activity leads to dissolution of cell-cell contacts and formation of stress fiber 
(Sahai et al., 2002). In NMuMG cells, mink lung cell line (Mv1Lu), pancreatic tumor 
cell line (BxPc3), and primary mouse keratinocytes, EMT induced by TGFβ-treatment 
has been shown to require activation of RhoA (Bhowmick et al., 2001). Blocking 
RhoA or ROCK activation inhibited stress fiber formation as well as changes in cell 
shape but did not affect E-cadherin integrity. Studies from renal proximal tubular cells 
support this notion. Activation of RhoA, not Smad, is responsible for the 
morphological change in TGFβ-induced EMT and inhibition of ROCK inhibits this 
effect (Tian et al., 2003). It is interesting to note that in ERp29-induced MET, 
morphological change is accompanied by reduction of stress fiber formation which is 
supported by the decrease of phosphorylated form of MLC. As mentioned earlier, the 
phosphorylation of MLC is mediated by ROCK.   
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Activation of multiple downstream pathways in ERp29-induced MET is reminiscent 
of modulation of multiple effectors in TGFβ-induced EMT. Furthermore, many 
regulators that have been demonstrated to be important mediators in TGFβ-induced 
EMT (i.e. E-cadherin repressors and formation of stress fiber via pMLC) are shown to 
be differentially regulated upon overexpression of ERp29. Therefore, it is tempting to 
raise the possibility that ERp29 is involved in TGFβ-induced EMT, possibly 
inhibiting Smad canonical pathway and/or RhoA non-canonical pathway.  
4.4 Restoration of apical-basal polarity  
Present study shows that in inducing epithelial morphology, ERp29 restores 
apical-basal polarity in both MDA-MB231 and BT549 cells (Figure 3-3 and 3-4). 
Initiation of cell polarity is a complex process involving polarity modules and 
junctional complexes which physically separate the apical and basal domains. It is 
proposed that polarity and tight junction proteins as well as actin cytoskeleton work 
intimately together to establish final epithelial polarity (reviewed in Godde et al., 
2010). The junctional complexes play a complicated role in polarization. On one hand, 
their formation is believed to drive polarization, on the other hand the formation of 
mature apical junctional complexes is often used as a benchmark of completed 
polarization. Recently, two opinions have been suggested in describing the 
establishment of apical-basal polarity; the classical model in which cell adhesions 
initiates polarization and non-classical model where cell polarization occurs without 
cell-cell contacts (reviewed in Wang et al., 2007). 
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Upon initiation of cell polarization cues (such as regulation of growth factors), cells 
rearrange their actin cytoskeleton which allows the apical distribution of Par complex 
protein, Par3. In the classical model, Par3 localization requires E-cadherin and is 
mediated by tight junction structural component junctional adhesion molecule-1 
(JAM1) and the adherens junction component nectin at cell-cell contact sites (Ebnet et 
al., 2001; Itoh et al., 2001; Takekuni et al., 2003). In contrast, initial cell-cell contacts 
have been shown not to be crucial, as activation of the polarity regulator LKB1 in 
single mammalian intestinal cells lacking junctions results in polarization; supporting 
non-classical model (Baas et al., 2004). Furthermore, in some cases Crumbs and Par 
complexes have been suggested to initiate polarity without adhesion (Wang et al., 
2007). In either model, redistribution of Par3 is then followed by separation of other 
members of polarity complexes as well as transportation of (or the rest of) cell-cell 
junction proteins to cell periphery. The polarity proteins and junctional proteins will 
then depend on each other for their maturation. For example, adherens junction 
component is needed to maintain Par3 at tight junctions and in turn Par3 has been 
shown to be important in tight junction formation as its depletion disrupts the tight but 
not adherens junctions (Halbleib et al., 2006). In addition, Par complex is established 
upon recruitment of Par6-aPKC complex by binding of Par6 to Par3 located at the 
tight junctions and downregulation of Par3 results in loss of cell polarity as it 
redistributes Par6-aPKC complex from cell membrane (Chen et al., 2006). 
 
 
Chapter 4: Discussions 
 70 
Considering the importance of Par3 in the establishment of apical basal polarity, it 
may play similar role in ERp29-induced MET. This might also be true even in BT549 
model where only a small portion of the upregulated Par3 is redistributed to cell 
periphery. Of note, small fraction of another polarity protein, PALS1, has been shown 
to be adequate for tight junction assembly (Straight et al., 2004). Overexpression of 
ERp29 induces rearrangement of actin cytoskeleton allowing localization of Par3 to 
cell membrane. This promotes the assembly of ZO1 and Scribble at cell-cell contact 
sites which together lead to restoration of epithelial polarization and morphology. 
Further investigation is needed to learn if other polarity and/or cell-cell junction 
modulators are involved in ERp29-induced MET.  
4.5 ERp29: functions in MET and secretion 
Present study demonstrates that overexpression of ERp29 restores epithelial 
morphology in breast cancer cells. Epithelial cells play critical roles in many normal 
physiologies (Baum et al., 2008; Yang et al., 2008). They cover organs and body 
cavities thereby imparting mechanical protection, mediate absorption, sensory, and 
secretion. Epithelia function in wide variety of biological processes from nutrient 
absorption in the intestines to gaseous exchange in the lungs to lactogenesis in the 
mammary gland. The last example is of particular interest as ERp29 is also known to 
mediate secretion of various entities, including proteins in milk production (see 
Introduction). 
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In mammary epithelia, permeability of epithelia is closely related to milk secretion 
where the number of tight junction strands varies between pregnant and lactating 
stages (Morgan et al., 1982). Decrease permeability during pregnancy is achieved 
through increasing the number, as well as organization, of tight junctions. This 
enhancement of tight junction barrier is thought to involve increased expression as 
well as phosphorylation of ZO1, which can be induced upon addition of prolactin or 
glucocorticoids (Singer et al., 1994). Therefore, tight junction components, in 
particular ZO1, is crucial for optimal milk secretion. Considering that the role of 
ERp29 as putative secretory protein has also been implicated in milk production 
(Mkrtchian et al., 2006), its ability in promoting MET (by inducing ZO1) might also 
contribute to the secretory function.   
It is also worth noting that the polarized trafficking machinery is an adaptation of the 
secretory and endocytic systems. In MDCK cells apical and basolateral polarity 
proteins are synthesized at the endoplasmic reticulum, transported to the Golgi 
complex and sorted at the trans golgi network into distinct apical and basolateral 
vesicular routes (Simons et al., 1990; Rodriguez-Boulan et al., 1992). This, again, 
suggests that the role of ERp29 in inducing MET (by restoring polarity and tight 
junction modulators to their proper location) might be interlinked with its secretory 
function.  
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4.6 ERp29: friend or foe? 
Association of ERp29 and cancer progression has been puzzling; studies have implied 
it as tumor suppressor as well as oncoprotein (Table 1-3). Current study has 
demonstrated the functional role of ERp29 in inducing MET and epithelial cell 
polarity, providing a novel insight into its tumor suppressive function in breast 
carcinogenesis. This notion, however, has to be taken with care as MET may be seen 
as both support or hindrance in metastasis.  
EMT has been implicated as a mechanism that mediates the escape of cancer cells 
from primary tumors therefore facilitating metastasis. Thus, molecular intervention 
that can counteract this transition by inducing MET, including ERp29, might be 
considered as tumor suppressor. This is supported by the finding that level of ERp29 
is downregulated in breast tumor samples compared to their normal counterparts and 
there exists a negative relationship between ERp29 and breast cancer stage/grade 
(Bambang et al., 2009b). In addition, overexpression of ERp29 inhibits tumor growth 
in vivo. Similar observations are found with a known tumor suppressor EphB3 whose 
expression is significantly reduced in advanced Dukes’ stage of colon cancer and 
overexpression induces MET in human colon cancer cells HT-29 (Chiu et al., 2009).  
On the other hand, MET has also been explored as an integral part of cancer 
progression by mediating the metastatic formation at secondary sites. Furthermore, 
overexpression of ERp29 has been shown to increase resistance to chemotherapeutic 
agent doxorobucin by attenuating its apoptotic effect (Zhang et al., 2010a). Thus, the 
presence or elevated level of ERp29 might essentially confer worse prognosis. Indeed, 
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study in bladder carcinoma cells reveals that although generated from same genetic 
background, more metastatic cell sublines acquire epithelial characteristics through 
MET (Chaffer et al., 2006). These epithelial-like sublines dramatically increased 
metastatic ability upon intracardiac or intratibial injection but not orthotopic 
inoculation, indicating the need of EMT for escape from primary tumor.  
Armed with information at hand, precise role of ERp29 in breast carcinogenesis, in 
particular metastasis, remains unclear. Mechanistic and experimental model studies on 
the involvement of ERp29 in cancer cell metastasis are vital in solving this 
uncertainty. It should be noted that, like TGFβ, ERp29 may act as both tumor 
suppressor and promoter; its downregulation may promote tumor progression in 
primary tumors, while upregulation of ERp29 in aggressive tumor cells may involve 
MET and thus facilitates distant metastasis in the late stage. In all, it is imperative to 
elucidate the pathological functions of ERp29 in cancer progression and to investigate 









Chapter 4: Discussions 
 74 
4.7 Conclusions 
Similar to other reticuloplasmins, ERp29 is involved in cancer progression. This study 
reveals that overexpression of ERp29 results in the induction of complete and 
incomplete MET in MDA-MB231 and BT549 breast cancer cells, respectively. These 
observations lead to the proposal of two potential mechanisms regulated by ERp29, 
leading to different aspects of MET (Figure 4-1).  
 
Figure 4-1 Proposed mechanism in ERp29-induced MET. Overexpression of ERp29 
activates two downstream pathways. The first includes regulation of actin cytoskeleton 
(possibly through downregulation of RhoA and/or inactivation of ROCK), tight junctions and 
polarity complexes. The second includes downregulation of E-cadherin repressors and 
subsequent regulation of epithelial and mesenchymal markers.  
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4.8 Future works 
The novel finding that ERp29 regulates MET provides the platform to better 
understand the role of ERp29 in breast cancer progression. However, it is not clear yet 
whether ERp29-induced MET inhibits metastasis by counteracting EMT or promotes 
metastasis as an independent mechanism. In previous study, ERp29 has been shown to 
inhibit primary tumor growth when ERp29-overexpressing MDA-MB231 cells are 
injected subcutaneously (Bambang et al., 2009b). Unfortunately, investigation on 
metastasis was not performed. Varying the site of inoculation allows examination of 
different stages of metastatic process (Chaffer et al., 2006). Metastatic growth 
observed following orthotopic injection demonstrates that cells are able to complete 
all metastatic stages including migration and invasion from primary tumor, 
intravasation to bloodstream, survival in the circulation, extravasation, as well as 
development of secondary tumor. Intercardiac injection reveals cells’ ability to survive 
in circulation, extravasate, and form metastatic growth. Direct injection at secondary 
sites bypasses all but the last stage of metastasis, namely the secondary tumor 
formation. Studies performed under these settings will shed light on the implication of 
ERp29-induced MET.  
It is proposed that regulation of RhoA and its effector ROCK might be the mechanism 
underlying ERp29-induced MET (Figure 4-1). To confirm this notion, examination of 
expression level, localization, as well as activation status of the above mentioned 
regulators is necessary. Furthermore, induction of MET by ERp29-overexpression has 
been associated with TGFβ-induced EMT. Therefore investigating the regulation of 
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TGFβ’s receptor, such as TβRI and TβRII, may prove useful. In addition, it might also 
be interesting to investigate if ERp29 inhibits TGFβ-induced EMT. Of note, inhibitor 
of TGFβ-induced EMT such as glucocorticoid dexamethasone, has been shown to 
promote MET (Zhang et al., 2010b). 
This study shows that overexpression of ERp29 regulates MET in mesenchymal-like 
MDA-MB231 cells and basal-like BT549 cells by restoring epithelial characteristics. 
The importance of ERp29 in maintaining epithelial integrity may be explored by 
downregulating the protein in epithelial MCF7 breast cancer cells, which express high 
level of ERp29. Preliminary study reveals that ERp29 knockdown accelerates 
proliferation rate, increases mesenchymal markers and decreases epithelial markers, 
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